Mesenchymal stem/stromal cells in stromal evolution and cancer progression

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Cammarota, Francesca ^a   Laukkanen, Mikko O ^a  

^a IRCCS SDN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; COLLAGEN; FIBRIN; PATIDEGIB; REACTIVE OXYGEN METABOLITE; SEPRASE; VASCULOTROPIN A;

ANAPLASTIC THYROID CANCER; BLOOD VESSEL PERMEABILITY; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL AUTONOMOUS DRUG RESISTANCE; CELL MIGRATION; CLINICAL EFFECTIVENESS; DESMOPLASIA; DRUG RESISTANCE; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROBLAST; GRAFT VERSUS HOST REACTION; HUMAN; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; NEOPLASM; NONHUMAN; ONCOLOGICAL PARAMETERS; PARENCHYMA CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; TARGET ORGAN; TUMOR MICROENVIRONMENT; TUMOR STROMA EVOLUTION;

EID: 84954556044     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/4824573     Document Type: Review

References (122)

1. E. R. Le Count, "Lymphoma, a benign tumor representing a lymph gland in structure, " The Journal of Experimental Medicine, vol. 4, no. 5-6, pp. 559-567, 1899.
2. I. Levin, "Changes in the tissue surrounding a growing tumor and the significance of the precancerous state, " Journal of Experimental Medicine, vol. 16, no. 2, pp. 149-154, 1912.
3. I. Levin, "The mechanisms of metastasis formation in experimental cancer, " Journal of Experimental Medicine, vol. 18, no. 4, pp. 397-405, 1913.
4. S. O. Tamimi and A. Ahmed, "Stromal changes in invasive breast carcinoma: an ultrastructural study, " Journal of Pathology, vol. 153, no. 2, pp. 163-170, 1987.
5. D. Zipori, M. Krupsky, and P. Resnitzky, "Stromal cell effects on clonal growth of tumors, " Cancer, vol. 60, no. 8, pp. 1757-1762, 1987.
6. F. R. Miller, D. McEachern, and B. E. Miller, "Growth regulation of mouse mammary tumor cells in collagen gel cultures by diffusible factors produced by normal mammary gland epithelium and stromal fibroblasts, " Cancer Research, vol. 49, no. 21, pp. 6091-6097, 1989.
7. C. E. P. van Roozendaal, B. van Ooijen, J. G. M. Klijn et al. , "Stromal influences on breast cancer cell growth, " British Journal of Cancer, vol. 65, no. 1, pp. 77-81, 1992.
8. X. Wu, C. Jin, F. Wang, C. Yu, and W. L. McKeehan, "Stromal cell heterogeneity in fibroblast growth factor-mediated stromalepithelial cell cross-talk in premalignant prostate tumors, " Cancer Research, vol. 63, no. 16, pp. 4936-4944, 2003.
9. M. Greenblatt and P. Shubi, "Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique, " Journal of the National Cancer Institute, vol. 41, no. 1, pp. 111-124, 1968.
10. D. G. Duda, K. S. Cohen, S. V. Kozin et al. , "Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors, " Blood, vol. 107, no. 7, pp. 2774-2776, 2006.
11. A. E. Woods and J. M. Papadimitriou, "The effect of inflammatory stimuli on the stroma of neoplasms: the involvement of mononuclear phagocytes, " Journal of Pathology, vol. 123, no. 3, pp. 165-174, 1977.
12. D. Lyden, K. Hattori, S. Dias et al. , "Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth, " Nature Medicine, vol. 7, no. 11, pp. 1194-1201, 2001.
13. K. L. Andarawewa, E. R. Motrescu, M.-P. Chenard et al. , "Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front, " Cancer Research, vol. 65, no. 23, pp. 10862-10871, 2005.
14. D. Bonnet and J. E. Dick, "Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, " Nature Medicine, vol. 3, no. 7, pp. 730-737, 1997.
15. S. K. Singh, C. Hawkins, I. D. Clarke et al. , "Identification of human brain tumour initiating cells, " Nature, vol. 432, no. 7015, pp. 396-401, 2004.
16. A. Santamaria-Martinez, J. Barquinero, A. Barbosa-Desongles et al. , "Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis, " Experimental Cell Research, vol. 315, no. 17, pp. 3004-3013, 2009.
17. G. van der Horst, L. Bos, and G. van der Pluijm, "Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma, " Molecular Cancer Research, vol. 10, no. 8, pp. 995-1009, 2012.
18. R. Liu, S. Wei, J. Chen, and S. Xu, "Mesenchymal stem cells in lung cancer tumor microenvironment: their biological properties, influence on tumor growth and therapeutic implications, " Cancer letters, vol. 353, no. 2, pp. 145-152, 2014.
19. A. Calon, E. Lonardo, A. Berenguer-Llergo et al. , "Stromal gene expression defines poor-prognosis subtypes in colorectal cancer, " Nature Genetics, vol. 47, pp. 320-329, 2015.
20. C. Isella, A. Terrasi, S. E. Bellomo et al. , "Stromal contribution to the colorectal cancer transcriptome, " Nature Genetics, vol. 47, pp. 312-319, 2015.
21. H. Choi, J. Sheng, D. Gao et al. , "Transcriptome analysis of individual stromal cell populations identifies stroma-tumor crosstalk in mouse lung cancer model, " Cell Reports, vol. 10, pp. 1187-1201, 2015.
22. J. A. Nagy, L. F. Brown, D. R. Senger et al. , "Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition, " Biochimica et Biophysica Acta-Reviews on Cancer, vol. 948, no. 3, pp. 305-326, 1989.
23. I. Freitas, G. F. Baronzio, V. Bertone et al. , "Stroma formation in Ehrlich carcinoma. I. Oedema phase. A mitosis burst as an index of physiological reoxygenation?" Anticancer Research, vol. 11, no. 2, pp. 569-578, 1991.
24. H. F. Dvorak, V. S. Harvey, P. Estrella, L. F. Brown, J. McDonagh, and A. M. Dvorak, "Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing, " Laboratory Investigation, vol. 57, no. 6, pp. 673-686, 1987.
25. M. Lohr, C. Schmidt, J. Ringel et al. , "Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma, " Cancer Research, vol. 61, no. 2, pp. 550-555, 2001.
26. J. A. Tuxhorn, G. E. Ayala, M. J. Smith, V. C. Smith, T. D. Dang, and D. R. Rowley, "Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling, " Clinical Cancer Research, vol. 8, no. 9, pp. 2912-2923, 2002.
27. H. F. Dvorak, N. S. Orenstein, A. C. Carvalho et al. , "Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products, " Journal of Immunology, vol. 122, no. 1, pp. 166-174, 1979.
28. E. Monaghan-Benson and K. Burridge, "The regulation of vascular endothelial growth factor-induced microvascular permeability requires Rac and reactive oxygen species, " The Journal of Biological Chemistry, vol. 284, no. 38, pp. 25602-25611, 2009.
29. C. DerMardirossian and G. M. Bokoch, "GDIs: central regulatory molecules in Rho GTPase activation, " Trends in Cell Biology, vol. 15, no. 7, pp. 356-363, 2005.
30. D. Fukumura, T. Gohongi, A. Kadambi et al. , "Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2604-2609, 2001.
31. D. B. McKay, "[3H]Noradrenaline accumulation in cultured bovine adrenal medullary cells: modulation of accumulation by nicotine, " Naunyn-Schmiedebergs Archives of Pharmacology, vol. 340, no. 6, pp. 610-616, 1989.
32. D. Zhao, L. Qin, P.-M. Bourbon, L. James, H. F. Dvorak, and H. Zeng, "Orphan nuclear transcription factor TR3/Nur77 regulates microvessel permeability by targeting endothelial nitric oxide synthase and destabilizing endothelial junctions, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 29, pp. 12066-12071, 2011.
33. C. A. Kunder, A. L. St John, and S. N. Abraham, "Mast cell modulation of the vascular and lymphatic endothelium, " Blood, vol. 118, no. 20, pp. 5383-5393, 2011.
34. H. F. Dvorak, "Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing, " The New England Journal ofMedicine, vol. 315, no. 26, pp. 1650-1659, 1986.
35. A. H. Klopp, L. Lacerda, A. Gupta et al. , "Mesenchymal stem cells promote mammosphere formation and decrease ECadherin in normal andmalignant breast cells, " PLoS ONE, vol. 5, no. 8, Article IDe12180, 2010.
36. H. F. Dvorak, J. A. Nagy, D. Feng et al. , "Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis, " Current Topics in Microbiology and Immunology, vol. 237, pp. 98-132, 1999.
37. M. Schmitt, F. Janicke, N. Moniwa, N. Chucholowski, L. Pache, and H. Graeff, "Tumor-associated urokinase-type plasminogen activator: biological and clinical significance, " Biological Chemistry Hoppe-Seyler, vol. 373, no. 7, pp. 611-622, 1992.
38. E. Zorio, J. Gilabert-Estelles, F. Espana, L. A. Ramon, R. Cosin, and A. Estelles, "Fibrinolysis: the key to new pathogenetic mechanisms, " Current Medicinal Chemistry, vol. 15, pp. 923-929, 2008.
39. J. A. Nagy, A. M. Dvorak, and H. F. Dvorak, "Vascular hyperpermeability, angiogenesis, and stroma generation, " Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 2, Article ID a006544, 2012.
40. E. DAsti, N. Magnus, B. Meehan, D. Garnier, and J. Rak, "Genetic basis of thrombosis in cancer, " Seminars inThrombosis and Hemostasis, vol. 40, no. 3, pp. 284-295, 2014.
41. H. F. Dvorak, A. M. Dvorak, E. J. Manseau, L. Wiberg, and W. H. Churchill, "Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression, " Journal of the National Cancer Institute, vol. 62, no. 6, pp. 1459-1472, 1979.
42. L. VanDeWater, P. B. Tracy, D. Aronson, K. G. Mann, and H. F. Dvorak, "Tumor cell generation of thrombin via functional prothrombinase assembly, " Cancer Research, vol. 45, no. 11, pp. 5521-5525, 1985.
43. C. Yapijakis, A. Bramos, A. M. Nixon, V. Ragos, and E. Vairaktaris, "The interplay between hemostasis and malignancy: the oral cancer paradigm, " Anticancer Research, vol. 32, no. 5, pp. 1791-1800, 2012.
44. S. S. McAllister and R. A. Weinberg, "The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis, " Nature Cell Biology, vol. 16, no. 8, pp. 717-727, 2014.
45. S. H. Barsky, C. N. Rao, G. R. Grotendorst, and L. A. Liotta, "Increased content of type V collagen in desmoplasia of human breast carcinoma, " American Journal of Pathology, vol. 108, no. 3, pp. 276-283, 1982.
46. O. Koperek, C. Scheuba, C. Puri et al. , "Molecular characterization of the desmoplastic tumor stroma in medullary thyroid carcinoma, " International Journal of Oncology, vol. 31, no. 1, pp. 59-67, 2007.
47. C. Scheuba, K. Kaserer, K. Kaczirek, R. Asari, and B. Niederle, "Desmoplastic stromal reaction in medullary thyroid cancer-an intraoperative "marker" for lymph node metastases, " World Journal of Surgery, vol. 30, no. 5, pp. 853-859, 2006.
48. O. Koperek, R. Asari, B. Niederle, and K. Kaserer, "Desmoplastic stromal reaction in papillary thyroid microcarcinoma, " Histopathology, vol. 58, no. 6, pp. 919-924, 2011.
49. O. Koperek, E. Akin, R. Asari, B. Niederle, and N. Neuhold, "Expression of hypoxia-inducible factor 1 alpha in papillary thyroid carcinoma is associated with desmoplastic stromal reaction and lymph node metastasis, " Virchows Archiv, vol. 463, no. 6, pp. 795-802, 2013.
50. A. Toullec, D. Gerald, G. Despouy et al. , "Oxidative stress promotes myofibroblast differentiation and tumour spreading, " EMBO Molecular Medicine, vol. 2, no. 6, pp. 211-230, 2010.
51. B. Z. Packard, V. V. Artym, A. Komoriya, and K. M. Yamada, "Direct visualization of protease activity on cells migrating in three-dimensions, "Matrix Biology, vol. 28, no. 1, pp. 3-10, 2009.
52. P. B. Gupta, T. T. Onder, G. Jiang et al. , "Identification of selective inhibitors of cancer stem cells by high-throughput screening, " Cell, vol. 138, no. 4, pp. 645-659, 2009.
53. M. A. McNiven, "Breaking away: matrix remodeling from the leading edge, " Trends in Cell Biology, vol. 23, no. 1, pp. 16-21, 2013.
54. A. L. Jackson, R. Chen, and L. A. Loeb, "Induction of microsatellite instability by oxidative DNA damage, " Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 21, pp. 12468-12473, 1998.
55. K. Ohuchida, K. Mizumoto, M. Murakami et al. , "Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions, " Cancer Research, vol. 64, no. 9, pp. 3215-3222, 2004.
56. A. E. Karnoub, A. B. Dash, A. P. Vo et al. , "Mesenchymal stem cells within tumour stroma promote breast cancer metastasis, " Nature, vol. 449, no. 7162, pp. 557-563, 2007.
57. S. Liu, C. Ginestier, S. J. Ou et al. , "Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks, " Cancer Research, vol. 71, no. 2, pp. 614-624, 2011.
58. K. McLean, Y. Gong, Y. Choi et al. , "Human ovarian carcinomaassociated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production, " Journal of Clinical Investigation, vol. 121, no. 8, pp. 3206-3219, 2011.
59. L. da Silva Meirelles, P. C. Chagastelles, and N. B. Nardi, "Mesenchymal stem cells reside in virtually all post-natal organs and tissues, " Journal of Cell Science, vol. 119, no. 11, pp. 2204-2213, 2006.
60. M. Studeny, F. C. Marini, R. E. Champlin, C. Zompetta, I. J. Fidler, and M. Andreeff, "Bone marrow-derived mesenchymal stem cells as vehicles for interferon-βdelivery into tumors, " Cancer Research, vol. 62, no. 13, pp. 3603-3608, 2002.
61. A. H. Klopp, E. L. Spaeth, J. L. Dembinski et al. , "Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment, " Cancer Research, vol. 67, no. 24, pp. 11687-11695, 2007.
62. S. Kidd, E. Spaeth, J. L. Dembinski et al. , "Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging, " Stem Cells, vol. 27, no. 10, pp. 2614-2623, 2009.
63. A. Sohni and C. M. Verfaillie, "Mesenchymal stem cells migration homing and tracking, " Stem Cells International, vol. 2013, Article ID 130763, 8 pages, 2013.
64. S. Lourenco, V. H. Teixeira, T. Kalber, R. J. Jose, R. A. Floto, and S. M. Janes, "Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors, "The Journal of Immunology, vol. 194, pp. 3463-3474, 2015.
65. E. L. Spaeth, J. L. Dembinski, A. K. Sasser et al. , "Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression, " PLoS ONE, vol. 4, no. 4, Article ID e4992, 2009.
66. G. Kharaishvili, D. Simkova, K. Bouchalova, M. Gachechiladze, N. Narsia, and J. Bouchal, "The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance, " Cancer Cell International, vol. 14, no. 1, article no. 41, 2014.
67. Y. Mao, E. T. Keller, D. H. Garfield, K. Shen, and J. Wang, "Stromal cells in tumor microenvironment and breast cancer, " Cancer andMetastasis Reviews, vol. 32, no. 1-2, pp. 303-315, 2013.
68. W. A. Schulz, M. Burchardt, and M. V. Cronauer, "Molecular biology of prostate cancer, "MolecularHuman Reproduction, vol. 9, no. 7-8, pp. 437-448, 2003.
69. H. Luo, G. Tu, Z. Liu, and M. Liu, "Cancer-associated fibroblasts: amultifaceted driver of breast cancer progression, " Cancer Letters, vol. 361, pp. 155-163, 2015.
70. Y. P. Choi, J. H. Lee, M.-Q. Gao et al. , "Cancer-associated fibroblast promote transmigration through endothelial brain cells in three-dimensional in vitro models, " International Journal of Cancer, vol. 135, no. 9, pp. 2024-2033, 2014.
71. R. Marlow, P. Strickland, J. S. Lee et al. , "SLITs suppress tumor growth In vivo by silencing Sdf1/Cxcr4 within breast epithelium, " Cancer Research, vol. 68, no. 19, pp. 7819-7827, 2008.
72. A. Prasad, A. Z. Fernandis, Y. Rao, and R. K. Ganju, "Slit protein-mediated inhibition of CXCR4-induced chemotactic and chemoinvasive signaling pathways in breast cancer cells, " The Journal of Biological Chemistry, vol. 279, no. 10, pp. 9115-9124, 2004.
73. P.-H. Chang, W. W. Hwang-Verslues, Y.-C. Chang et al. , "Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/beta-catenin pathway, " Cancer Research, vol. 72, no. 18, pp. 4652-4661, 2012.
74. M. C. Stella, L. Trusolino, and P. M. Comoglio, "The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis, " Molecular Biology of the Cell, vol. 20, no. 2, pp. 642-657, 2009.
75. A. Takahashi, G. Ishii, S. Neri et al. , "Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth, " Oncotarget, vol. 6, pp. 9531-9541, 2015.
76. K. Anton, D. Banerjee, and J. Glod, "Macrophage-associated mesenchymal stem cells assume an activated, migratory, proinflammatory phenotype with increased IL-6 and CXCL10 secretion, " PLoS ONE, vol. 7, no. 4, Article ID e35036, 2012.
77. R. S. Waterman, S. L. Tomchuck, S. L. Henkle, and A. M. Betancourt, "A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype, " PLoS ONE, vol. 5, no. 4, Article ID e10088, 2010.
78. L. Lacerda, B. G. Debeb, D. Smith et al. , "Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model, " Breast Cancer Research, vol. 17, article 42, 2015.
79. M. Di Nicola, C. Carlo-Stella, M. Magni et al. , "Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli, " Blood, vol. 99, no. 10, pp. 3838-3843, 2002.
80. R. Ramasamy, E. W.-F. Lam, I. Soeiro, V. Tisato, D. Bonnet, and F. Dazzi, "Mesenchymal stemcells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth, " Leukemia, vol. 21, no. 2, pp. 304-310, 2007.
81. M. Takeda, T. Mikami, Y. Numata, M. Okamoto, and I. Okayasu, "Papillary thyroid carcinoma with heterotopic ossification is a special subtype with extensive progression, " American Journal of Clinical Pathology, vol. 139, no. 5, pp. 587-598, 2013.
82. H. Kuribayashi, K. Tsuta, E. Mizutani et al. , "Clinicopathological analysis of primary lung carcinoma with heterotopic ossification, " Lung Cancer, vol. 64, no. 2, pp. 160-165, 2009.
83. M. N. Rumi, G. S. Deol, K. P. Singapuri, and V. D. Pellegrini Jr. , "The origin of osteoprogenitor cells responsible for heterotopic ossification following hip surgery: an animal model in the rabbit, " Journal of Orthopaedic Research, vol. 23, no. 1, pp. 34-40, 2005.
84. C. A. OBrien, A. Pollett, S. Gallinger, and J. E. Dick, "A human colon cancer cell capable of initiating tumour growth in immunodeficient mice, " Nature, vol. 445, no. 7123, pp. 106-110, 2007.
85. S. A. Patel, M. A. Dave, S. A. Bliss et al. , "Treg/Th17 polarization by distinct subsets of breast cancer cells is dictated by the interaction with mesenchymal stem cells, " Journal of Cancer Stem Cell Research, vol. 2, Article ID e1003, 2014.
86. B. G. Cuiffo, A. Campagne, G. W. Bell et al. , "MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis, " Cell Stem Cell, vol. 15, no. 6, pp. 762-774, 2014.
87. K. Denzer, M. J. Kleijmeer, H. F. G. Heijnen, W. Stoorvogel, and H. J. Geuze, "Exosome: from internal vesicle of the multivesicular body to intercellular signaling device, " Journal of Cell Science, vol. 113, part 19, pp. 3365-3374, 2000.
88. S. Atay, S. Banskota, J. Crow, G. Sethi, L. Rink, and A. K. Godwin, "Oncogenic KIT-containing exosomes increasegastrointestinal stromal tumor cell invasion, " Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 2, pp. 711-716, 2014.
89. K. C. Vallabhaneni, H. Haller, and I. Dumler, "Vascular smooth muscle cells initiate proliferation of mesenchymal stem cells by mitochondrial transfer via tunneling nanotubes, " StemCells and Development, vol. 21, no. 17, pp. 3104-3113, 2012.
90. V. Luga, L. Zhang, A. M. Viloria-Petit et al. , "Exosomesmediate stromal mobilization of autocrineWnt-PCP signaling in breast cancer cell migration, " Cell, vol. 151, no. 7, pp. 1542-1556, 2012.
91. P. K. Lim, S. A. Bliss, S. A. Patel et al. , "Gap junction-mediated import of microRNA frombonemarrow stromal cells can elicit cell cycle quiescence in breast cancer cells, " Cancer Research, vol. 71, no. 5, pp. 1550-1560, 2011.
92. M. D. Milsom and A. Trumpp, "Bridging the information gap, " Nature Immunology, vol. 12, no. 5, pp. 377-379, 2011.
93. E. T. Ishikawa, D. Gonzalez-Nieto, G. Ghiaur et al. , "Connexin-43 prevents hematopoietic stem cell senescence through transfer of reactive oxygen species to bone marrow stromal cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 23, pp. 9071-9076, 2012.
94. G. Rappa, J. Mercapide, and A. Lorico, "Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity, " The American Journal of Pathology, vol. 180, no. 6, pp. 2504-2515, 2012.
95. J. L. Spees, S. D. Olson, M. J. Whitney, and D. J. Prockop, "Mitochondrial transfer between cells can rescue aerobic respiration, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1283-1288, 2006.
96. S. Strassburg, N. W. Hodson, P. I. Hill, S. M. Richardson, and J. A. Hoyland, "Bi-directional exchange of membrane components occurs during co-culture of mesenchymal stem cells and nucleus pulposus cells, " PLoS ONE, vol. 7, no. 3, Article ID e33739, 2012.
97. M. D. Castellone, L. E. Laatikainen, J. P. Laurila et al. , "Brief report:mesenchymal stromal cell atrophy in coculture increases aggressiveness of transformed cells, " StemCells, vol. 31, no. 6, pp. 1218-1223, 2013.
98. K. Mandel, Y. Yang, A. Schambach, S. Glage, A. Otte, and R. Hass, "Mesenchymal stem cells directly interact with breast cancer cells and promote tumor cell growth in vitro and in vivo, " Stem Cells and Development, vol. 22, no. 23, pp. 3114-3127, 2013.
99. M. Pietila, P. Lehenkari, P. Kuvaja et al. , "Mortalin antibodyconjugated quantum dot transfer from human mesenchymal stromal cells to breast cancer cells requires cell-cell interaction, " Experimental Cell Research, vol. 319, no. 18, pp. 2770-2780, 2013.
100. M. Abercrombie, "The bases of the locomotory behaviour of fibroblasts, " Experimental Cell Research, vol. 8, pp. 188-198, 1961.
101. H. Eagle, G. E. Foley, H. Koprowski, H. Lazarus, E. M. Levine, and R. A. Adams, "Growth characteristics of virus-transformed cells. Maximum population density, inhibition by normal cells, serum requirement, growth in soft agar, and xenogeneic transplantability, " The Journal of Experimental Medicine, vol. 131, no. 4, pp. 863-879, 1970.
102. E. I. Azzam, S. M. de Toledo, and J. B. Little, "Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from-particle irradiated to nonirradiated cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 2, pp. 473-478, 2001.
103. Q. Huang, F. Li, X. Liu et al. , "Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy, " Nature Medicine, vol. 17, no. 7, pp. 860-866, 2011.
104. A. H. Klopp, A. Gupta, E. Spaeth, M. Andreeff, and F. Marini III, "Concise review: dissecting a discrepancy in the literature: domesenchymal stemcells support or suppress tumor growth?" Stem Cells, vol. 29, no. 1, pp. 11-19, 2011.
105. H. Niess, J. C. von Einem, M. N. Thomas et al. , "Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial, "BMC Cancer, vol. 15, article 237, 2015.
106. F. Baron, C. Lechanteur, E. Willems et al. , "Cotransplantation of mesenchymal stem cells might prevent death from graftversus-host disease (GVHD) without abrogating graft-versustumor effects afterHLA-mismatched allogeneic transplantation following nonmyeloablative conditioning, " Biology of Blood and Marrow Transplantation, vol. 16, pp. 838-847, 2010.
107. J. Kurtzberg, S. Prockop, P. Teira et al. , "Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients, " Biology of Blood and Marrow Transplantation, vol. 20, no. 2, pp. 229-235, 2014.
108. M. L. MacMillan, B. R. Blazar, T. E. DeFor, and J. E. Wagner, "Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial, " Bone Marrow Transplantation, vol. 43, no. 6, pp. 447-454, 2009.
109. H. M. Lazarus, O. N. Koc, S. M. Devine et al. , "Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients, " Biology of Blood and Marrow Transplantation, vol. 11, no. 5, pp. 389-398, 2005.
110. S. Corso and S. Giordano, "Cell-autonomous and non-cellautonomous mechanisms of HGF/MET-driven resistance to targeted therapies: frombasic research to a clinical perspective, " Cancer Discovery, vol. 3, no. 9, pp. 978-992, 2013.
111. K. P. Olive, M. A. Jacobetz, C. J. Davidson et al. , "Inhibition of Hedgehog signaling enhances delivery of chemotherapy in amouse model of pancreatic cancer, " Science, vol. 324, no. 5933, pp. 1457-1461, 2009.
112. G. L. Beatty and Y. Paterson, "IFN-γcan promote tumor evasion of the immune systemin vivo by down-regulating cellular levels of an endogenous tumor antigen, "The Journal of Immunology, vol. 165, no. 10, pp. 5502-5508, 2000.
113. M. Mersmann, A. Schmidt, J. F. Rippmann et al. , "Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas, " International Journal of Cancer, vol. 92, no. 2, pp. 240-248, 2001.
114. R.-D. Hofheinz, S.-E. Al-Batran, F. Hartmann et al. , "Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer, " Onkologie, vol. 26, no. 1, pp. 44-48, 2003.
115. A. M. Scott, G. Wiseman, S. Welt et al. , "A phase I doseescalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer, " Clinical Cancer Research, vol. 9, no. 5, pp. 1639-1647, 2003.
116. P. C. Schuberth, C. Hagedorn, S. M. Jensen et al. , "Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells, " Journal of Translational Medicine, vol. 11, no. 1, article 187, 11 pages, 2013.
117. J. Lee, M. Fassnacht, S. Nair, D. Boczkowski, and E. Gilboa, "Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts, " Cancer Research, vol. 65, no. 23, pp. 11156-11163, 2005.
118. S. Gottschalk, F. Yu, M. Ji, S. Kakarla, and X.-T. Song, "A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading, " PLoS ONE, vol. 8, no. 12, Article IDe82658, 2013.
119. M. Loeffler, J. A. Kruger, A. G. Niethammer, and R. A. Reisfeld, "Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake, " The Journal of Clinical Investigation, vol. 116, no. 7, pp. 1955-1962, 2006.
120. X. C. Li, X. L. Lu, and H. H. Chen, " α-Tocopherol treatment ameliorates chronic pancreatitis in an experimental rat model induced by trinitrobenzene sulfonic acid, " Pancreatology, vol. 11, no. 1, pp. 5-11, 2011.
121. A. Kuno, T. Yamada, K. Masuda et al. , "Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis inmaleWistar Bonn/Kobori rats, " Gastroenterology, vol. 124, no. 4, pp. 1010-1019, 2003.
122. A. V. Salnikov, N.-E. Heldin, L. B. Stuhr et al. , "Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma, " International Journal of Cancer, vol. 119, no. 12, pp. 2795-2802, 2006.